VNRX
VolitionRx Limited0.2421
-0.0016-0.66%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
29.73MP/E (TTM)
-Basic EPS (TTM)
-0.23Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
VolitionRx raises $6M via offering
VolitionRx closed a $6.0 million public offering on October 14, 2025, selling 11,550,000 shares and warrants at $0.52 each, with net proceeds of $5.4 million earmarked for R&D, clinical studies, and potential acquisitions. Cash stood at a mere $0.3 million as of September 30, 2025, underscoring the infusion's urgency. Warrants exercise at $0.60 over five years. Yet dilution looms large.
10-Q
Q2 FY2025 results
VolitionRx posted Q2 revenues of $406.7K, edging up 3% y/y but dipping 12% q/q on softer product sales, while services jumped 39% y/y from Nu.Q Discover demand. Operating loss narrowed to $6.3M from $7.0M y/y, thanks to 27% lower R&D spend after wrapping clinical trials and trimming headcount. Net loss improved to $6.3M, or $(0.06) per diluted share on 102.7M shares, versus $(0.08) last year; the EPS tracks with shares outstanding, no anti-dilution flags. Cash burned $10.6M YTD on ops, ending at $2.3M with $6.8M long-term debt and a fresh $7.5M convertible note (net $3.3M after discounts) issued May 2025 for runway. Free cash flow not disclosed in the 10-Q. Yet funding remains tight. Competition in diagnostics heats up.
CODX
Co-Diagnostics, Inc.
0.25-0.02
CVRX
CVRx, Inc.
8.32+0.14
NSRX
Nasus Pharma Ltd.
6.80+0.00
NUTX
Nutex Health Inc.
171.72-4.06
NVCR
NovoCure Limited
12.93-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
QTIH
QT Imaging Holdings, Inc.
6.10-0.02
VRAX
Virax Biolabs Group Limited
0.40-0.01
VTAK
Catheter Precision, Inc.
2.19-0.04
VYCO
Vycor Medical, Inc.
0.16+0.00